CURRICULUM VITAE RICHARD F. BERGSTROM, PH.D. OCTOBER 2011 PERSONAL DATA EDUCATION
Taylor University, Upland, IN, Major: Chemistry
University of Pittsburgh, School of Pharmacy, Pittsburgh, PA, Bachelor of
Butler University, College of Pharmacy, Indianapolis, IN, Master of Science
in Pharmacology (Thesis Advisor: Dr. James E. Berger and Dr. John F. Quay at Eli Lilly and Company)
University of Michigan, School of Pharmacy, Ann Arbor, MI, Doctor of
Philosophy Degree Pharmaceutical Chemistry (Pharmacokinetics) (Thesis Advisor: Dr. John G. Wagner)
EMPLOYMENT:
Butler University College of Pharmacy and Health Sciences
Professor or Pharmaceutical Sciences and Director of Research Alliances
Eli Lilly and Company, Indianapolis, IN, Research Global Pharmacokinetics
Pharmacodynamics and Trial Simulations, Lilly Research Laboratories Research Fellow
Eli Lilly and Company, Indianapolis, IN, Staff Member Lilly Laboratory for
Clinical Research, Indiana University Hospital.
Eli Lilly and Company, Indianapolis, IN, Staff Member Lilly Laboratory for
Clinical Research, Wishard Memorial Hospital.
Eli Lilly and Company, Indianapolis, IN, Parenteral Products Development,
Montefiore Hospital, Pittsburgh, PA, Pharmacy Staff Intern
CONSULTING APPOINTMENTS
RFBergstrom PK/PD Consulting LLC, Indianapolis, IN, Principal
Assignments/Projects: Centurion Clinical Research, LLC (2009); Eli Lilly and Company (2010), EMD Millipore, the Life Science Division of Merck KGaA of Germany (2010-present), Transpharma Medical Ltd (2010-present); BetaCat Pharmaceuticals, LLC (2011-present)
Anson Group Consulting LLC, Indianapolis, IN, Regulatory Advisor
YourEncore, Indianapolis, IN, PK/PD and Due Diligence Consulting
Assignments/Projects: Eli Lilly and Company, Roche
ACADEMIC APPOINTMENTS
Adjunct Assistant Professor of Pharmacology and Toxicology, Indiana
University School of Medicine, Division of Pharmacology and Toxicology
Adjunct Professor of Medicine, Indiana University School of Medicine,
Professor of Pharmaceutical Sciences and Director of Research Alliances,
Butler University, College of Pharmacy and Health Sciences
PHARMACY LICENSE HONORS AND AWARDS
Lilly Research Laboratories, President’s Recognition Award
Fellow - American Association of Pharmaceutical Scientists
Food and Drug Administration Commissioner's Special Citation,
American Foundation for Pharmaceutical Education, Manufacturing and
Industrial Pharmacy Fellow, The University of Michigan
Phi Lambda Upsilon Honorary Chemical Society (1978)
Merck Award Outstanding Achievement in Pharmaceutical Chemistry,
Rho Chi Scholarship Award, Pharmacy Honor Society
SCIENTIFIC AND RESEARCH ACTIVITES Drug Development PK/PD Project Responsibilities 1980-1982:
Benoxaprofen, Oraflex® non-steroidal anti-inflammatory NDA Submission, Drug Interactions (probenecid, ASA), Protein Binding
Nizatidine, LY139037, Axid®, Axid-AR™ United States NDA 20-555 (1996), PK/PD Consultant for Whitehall/Robbins prescription to OTC switch Areas of PK/PD Research: Clinical Pharmacology (Gastric Acid pH Effect and Sectrtion), Absolute Bioavailability (IV versus oral), Drug Interactions, Human 14C-labeled metabolism (IV and oral), Bioavailability/Bioequivalence (150 mg vs 300 mg capsules)
Fluoxetine, LY110140, Prozax®, Serafem® Prozac Weekly™ United States NDA 18-936 (1985), European Countries MAA (decentralized individual submissions), and Japan NDA (2001). Areas of PK/PD Research: Clinical Pharmacology, Enantiomer Selective Pharmacokinetics and Metabolism, Human 14C-labeled metabolism studies, Drug-Interactions (tricyclics, CYP2D6 inhibitor, CYP1A2 substrates terfenadine), Special Populations Studies (elderly, renally impaired, hepatically impaired, pediatric, adolescent), Bioavailability/Bioequivalence (alternative dosage forms: liquid, tablets, capsule strengths, delayed release Prozac Weekly capsules), Population Pharmacokinetics.
Olanzapine, LY170053, Zyprexa®, Symbyax®, Zyprexa® Zydis™, Relprevv™ NDA 20-592 (olanzapine original NDA), Clinical Pharmacology, Drug Interactions (theophylline, impramine), Bioavailability/Bioequivalence (tablets vs capsules), Special Populations (renally impaired, elderly, hepatically impaired), Population Pharmacokinetics NDA 21-086 (olanzapine rapidly disintegrating tablet, Zydis) Bioavailability/Bioequivalence (Zydis vs standard oral dose) NDA 21-520 (olanzapine fluoxetine fixed dose combinations) NDA 21-253 (olanzapine intramuscular injection) rapidly acting IM injection, PK/PD for IM administration, bioavailability/bioequivalence. NDA 22-173 (olanzapine pamoate depot) PK/DP of a depot drug product
Duloxetine, LY248686, Cymbalta®, Yentreve® NDA 21-147 (2001, delayed release capsules), MAA Clinical Pharmacology, Special Populations, Bioavailability/Bioequivalence, Drug Interactions, Metabolism (CYP2D6, CYP1A2, inhibitors and other substrates)
Editorial Advisory Board 2000-2002:
Journal Reviewer AAPS Journal AAPS PharmSciTech Antimicrobial Agents and Chemotherapy
Biopharmaceutics and Drug Disposition British Journal of Clinical Pharmacology Clinical Pharmacology and Therapeutics Drug Metabolism and Disposition Journal of Pharmaceutical Sciences Pharmaceutical Research
SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS American Pharmacists Association Academy of Pharmaceutical Sciences American Association of Pharmaceutical Scientists
• Primary Section: Pharmacokinetics Pharmacodynamics
• PPDM Section Abstract Screener (1990)
• PPDM Executive Committee (1991-1993)
• AAPS Strategic Planning Committee (1993)
• AAPS Executive Council Member at Large (1996-1998)
• AAPS Chair Publication Board (2001-2002)
• AAPS Nominations Program Review Team (2004)
• AAPS Fellows Selection Committee (2006 – 2008)
• PPDM Fellows Review Committee (2009 – 2010)
Indiana Ohio Discussion Group
• Founding Committee (1987), Chair (1988-89)
American College of Clinical Pharmacology
ASCPT American Society for Clinical Pharmacology and Therapeutics International Society for the Study of Xenobiotics TEACHING ACTIVITIES Indiana University School of Medicine F813
Clinical Pharmacokinetics (Indiana University School of Medicine, Department of Pharmacology and Toxicology): graduate level course taught every other year from 1986 until present covering the fundamental basis of PK/PD as they apply to new drug development.
Physiologic Disposition of Drugs and Pharmacogenomics (Indiana University School of Medicine, Department of Pharmacology and Toxicology): graduate level course taught every other year from 1985 until present covering the fundamentals of PK, metabolism, bioanalytical analysis, and genomics
Butler University College of Pharmacy and Health Sciences RX422
Industrial Pharmacy: Pre-formulation and Product Development
BIBLIOGRAPHY - ABSTRACTS
Kay, D.R., Wexler, D., Agabeyoglu, I.T., Bergstrom, R.F., Sakmar, E., and Wagner, J.G. Clinical Pharmacokinetics of Prednisolone and Prednisone in Immune Disease Patients Receiving Chronic Prednisone Therapy. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 11(2):96, Nov. 18, 1981.
Bergstrom, R.F., DeSante, K.A., Nash, J.F., and Ridolfo, A.S. Pharmacokinetic Interaction of Benoxaprofen and Probenecid. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci., 11(2):137, Nov. 18, 1981.
Bergstrom, R.F., Galloway, J.A., Root, M.A., and Spradlin, C.T. The Bioavailability Index for Insulin. Toronto International Workshop on Insulin and Portable Delivery Systems, Toronto, Canada, June 9, 1982.
Brier, G.L., Bergstrom, R.F., Black, H.R., Reynolds, J., Siders, J.A., and Bahn, N.A. Evaluation of the Dynatech Microelisa Reader for Anaerobic M.I.C. Determination. Abstract ICAAC, October, 1982.
McNay, J.L., Bechtol, L.D., Miner, D.S., and Bergstrom, R.F. Hydroxylation Activity Determines Disposition of Penbutolol in Man. Abstracts: II World Conference on Clin. Pharmacol. Ther., Washington, D.C.: Pharmacokinetics II (79):14, Aug. 1, 1983.
DeSante, K., Wolen, R., Bergstrom, R., Hatcher, B., Spradlin, C., and Lemberger, L. Determination of the Bioavailability and Dose Proportionality of Nabilone Using Stable Isotope Technology. Abstracts: II World Conference on Clin. Pharmacol. Ther., Washington, D.C.: Pharmacokinetics IV (280):48, Aug. 3, 1983.
Callaghan, J.T., Bergstrom, R.F., and Obermeyer, B.D. Pharmacokinetic-Pharmacodynamic Evaluation of Nizatidine, A New H2-Antagonist. Abstracts: II World Conference on Clin. Pharmacol. The., Washington, D.C.: Gastrointestinal, Histamine and Antagonists I (402):69, August 2, 1983.
Farid, N.A., Ziege, E.A., Bergstrom, R.F. and Lemberger, L. Physiologic Disposition and the Steady State Pharmacokinetics of Tomoxetine. Abstracts: II World Conference on Clin. Pharmacol. Ther., Washington, D.C.: Metabolism (663):114, August 4, 1983.
Aronoff, G.R., Pottrate, S.T., Sloan, R.S., Bergstrom, R.F. and Lemberger, L. Elimination Kinetics of Fluoxetine in Patients with Impaired Renal Function. Abstracts: II World Conference on Clin. Pharmacol. Ther., Washington, D.C.: Antidepressants (515):88, August 4, 1983.
10. Bergstrom, R.F., Farid, K.Z., McClurg, J.E., and Lemberger, L. The Pharmacokinetics of
Fluoxetine in Elderly Subjects. Abstracts: II World Conference on Clin. Pharmacol. Ther., Washington, D.C.: Drugs and the Elderly (699):120, August 4, 1983.
11. Bergstrom, R., Wolen, R., Dhahir, P., Hatcher, B., Werner, N. and Lemberger, L. Effect
of Food on the Absorption of Fluoxetine in Normal Subjects. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 14(1):100, May 10, 1984.
12. Knadler, M.P., Rubin, A., Bergstrom, R.F., and Callaghan, J.T. Effects of Gelusil,
Charcoal, and Propantheline on the Bioavailability of the H2-Blocker Nizatidine. The Pharmacologist 26(3): 236, Abstract 599, 1984.
13. Farid, N.A., Bergstrom, R.F., Ziege, E.A., and Lemberger, L. The Effect of Food on the
Relative Bioavailability of Tomoxetine and Intersubject Differences in Metabolism. p 1118 #4137, FASEB 69th Annual Meeting, Anaheim, CA, April, 1985.
14. Knadler, M.P., Bergstrom, R.F., Callaghan, J.T. and Rubin, A. Nizatidine, An H2-
Blocker: Its Metabolism and Dispostiion in Man. The Pharmacologist 27(3): 180, Abstract 383, 1985.
15. Rowe, H., Lemberger, L., Bergstrom, R., Hardison, D., Barrett, J. The Effect of Co-
administration of Fluoxetine and Diazepam on Psychomotor and Physiologic Responses. The Pharmacologist 27(3): 196, Abstract 462, 1985.
16. Bergstrom, R.F., Wolen, R.L., Lemberger, L., Dhahir, P., and Barrett, J.L. Fluoxetine
Single Dose-Multiple Dose Kinetics. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 15(2):137, October 21, 1985.
17. DeLong, A.F., Bergstrom, R.F., Lemberger, L., Barrett, J.L., and Doedens, D.J.
Fluoxetine-Secobarbital Interaction in Humans. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 15(2):149, October 21, 1985.
18. Callaghan, J.T., Farid, N.A., Bergstrom, R.F., Ziege, E.A., and Marshall, W.S. Clinical
Observations and the Single Dose and Steady State Pharmacokinetics of LY171883, A New Leukotriene D4-Antagonist, In Man., Abstract 212 in Annals of Allergy 55(part II):278, October, 1985.
19. Bergstrom, R.F., van Lier, R.B.L., Lemberger, L., and Tenbarge, J.L. Absolute
Bioavailability of Fluoxetine in Beagle Dogs. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 16(1):126, March 17, 1986.
20. Bergstrom, R.F., Wolen, R.L., Lemberger, L., Tenbarge, J.L., and Masco, H.L.
Fluoxetine Steady State Pharmacokinetics in Depressed Patients. Abstracts of Am. Pharm. Assn. Acad. Pharm. Sci. 16(1):125, March 17, 1986.
21. Aronoff, G.R., Sloan, R.S., Bopp, R.J., Walters, J.B., Bergstrom, R.F., and Callaghan,
J.T. Nizatidine Kinetics in Patients with Renal Insufficiency. Clin. Pharmacol. Ther. 39(2):178, 1986.
22. Callaghan, J.T., Bergstrom, R.F., Knadler, M.P., and Rubin, A. Nizatidine (N)
Disposition in Elderly Subjects (E). Clin. Pharmacol. Ther. 39(2):185, 1986.
23. Lemberger, L., Farid, N.A., Bergstrom, R.F., and Wolen, R.L. The Pharmacology and
Physiologic Disposition of Fluoxetine. Satellite - Drugs Regulating Food Intake and Energy Balance, Rome, Italy, September 22-25, 1986.
24. Bergstrom, R.F., Lemberger, L., and Hatcher, B.L. Evaluation of the Kinetics of
Morphine When Administered Alone or After Fluoxetine. Am. Assn. Pharm. Sci. 1st Annual Meeting, Washington, D.C., November 3, 1986, Pharm. Res 3(6):106S, 1986.
25. Farid, N.A., Bergstrom, R.F., Lemberger, L., Ziege, E.A., Tenbarge, J., Wolen, R.L., and
Dhahir, P.H. Studies on the Disposition of Fluoxetine at Steady State in Man with the Aid of Stable and Radioactive Isotopes. Collegium Internationale Neuropsycho Pharmaologieum, 15th CINP Congress, San Juan, Puerto Rico, December 14-17, 1986.
26. Murdoch, A.A., Shamblen, E.C., Lasseter, K.C., Rubin, A., Knadler, M.P., Bergstrom,
R.F., and Callaghan, J.T. Nizatidine Pharmacokinetics in Hepatic Disease. Associates of Clinical Pharmacology, Spring Meeting, J. Clin. Res. Drug Dev. 1 _:233, 1987.
27. Bergstrom, R.F., Lemberger, L., Kuhlthau, J.M., and Kisicki, J.C. Fluoxetine
Bioequivalence 10 vs 20 mg Capsules. Am. Assn. Pharm. Sci. 3rd Annual Meeting, Orlando , FL, November 3, 1988, Pharm. Res. 5(10):S-166, 1988.
28. Bergstrom, R.F., Lemberger, L., Russell, D.G., and Kisicki, J.C. Fluoxetine
Pharmacokinetics in Obese Women. Am. Assn. Pharm. Sci. 3rd Annual Meeting, Orlando , FL, November 3, 1988, Pharm. Res. 5(10):S-158, 1988.
29. Obermeyer, B.D., Bergstrom, R.F., Callaghan, J.T., Golichowsky, A., Knadler, M.P., and
Rubin, A. Secretion of Nizatidine into Human Breast Milk. The Pharmacologist 30(3): 1988.
30. Feher, M.D., Lucas, R.A., Farid, N.A., Idle, J.R., Bergstrom, R.F., Lemberger, L., and
Sever, P.S. Single Dose Pharmacokinetics of Tomoxetine in Poor and Extensive Metabolisers of Debrisoquine. Br. J. Clin. Pharmacol. 26:231, 1988.
31. Wolen, R.L., Bergstrom, R.F., Tenbarge J.B., and Lemberger, L. Fluoxetine Enantiomer
Disposition in Plasma and Urine of Normal Subjects and Patients. Am. Assn. Pharm. Sci. 4th Annual Meeting, Atlanta, GA, October 25, 1989, Pharm. Res. 6(9):S-221, 1989.
32. Bergstrom, R.F., Lemberger, L., Kuhlthau, J.M., and Kisicki, J.C. Fluoxetine:
Comparative Bioequivalence Studies with 60 mg Capsules and Tablets. Am. Assn. Pharm. Sci. 4th Annual Meeting, Atlanta, GA, October 25, 1989, Pharm. Res. 6(9):S-227, 1989.
33. Schwinghammer, T.L., Kroboth, P.D., Bergstrom, R.F., and Callaghan, J.T. The Effect
of Study Design on the Pharmacodynamics of Nizatidine. Am. College of Clin. Pharm. Annual Meeting, August 5, 1990, Pharmacotherapy 10(3):236, 1990.
34. Bergstrom, R.F., Lemberger, L., Cerimele, B.J., Wolen, R.L., and Kisicki, J.C. Relative
Bioequivalence of a Fluoxetine Oral Solution Versus the Marketed Capsule. Am. Assn. Pharm. Sci. 5th Annual Meeting, Las Vegas, NV, November 5, 1990, Pharm. Res. 7(9):S-251, 1990.
35. Bergstrom, R.F., Lemberger, L., and Peyton, A.L. Drug Interaction Between Fluoxetine
and the Tricyclic Antidepressants Imipramine and Desipramine. Am. Assn. Pharm. Sci. 5th Annual Meeting, Las Vegas, NV, November 5, 1990, Pharm. Res. 7(9):S-254, 1990.
36. Bergstrom, R.F., Beasley, C.M. Jr, Levy, N.B., Dubey, A.K., Blumenfield, M.,
Goodman, A., and Solomon, R.J. Fluoxetine Pharmacokinetics after Daily Doses of 20-mg Fluoxetine in Patients with Severely Impaired Renal Function. Am. Assn. Pharm. Sci. 6th Annual Meeting, Washington, DC, November 18, 1991, Pharm. Res. 8(10):S-294, 1991.
37. Peyton, A.L., Lemberger, L., Rutkowski, K., Wolen, R.L., Bergstrom, R.F., Haynes, T.,
and Ziege, E.A. Differential Disposition and Protein Binding of Fluoxetine and Norfluoxetine Enantiomers after Administration of Racemic Fluoxetine. Am. Assn. Pharm. Sci. 6th Annual Meeting, Washington, DC, November 18, 1991, Pharm. Res. 8(10):S-308, 1991.
38. Bergstrom, R.F., Wolen, R.L., Peyton, A.L., Goodwin, M.R., Kasper, S.C., Barton, R.,
Schwertschlag U., and Lemberger, L. Pharmacokinetics of R- and S-Fluoxetine Enantiomers and the Effect of P450IID6 Activity on their Disposition in Man. Am. Assn. Pharm. Sci. 7th Annual Meeting, San Antonio, TX, November 18, 1991, Pharm. Res. 9(10):S-306, 1992.
39. Seger, M.E., Bergstrom, R.F., Schwertschlag, U.S., and DeLong, A.F. Pharmacokinetics
of Dapoxetine after Single Oral Doses Given During A Phase I Clinical Evaluation. Am. Assn. Pharm. Sci. 7th Annual Meeting, San Antonio, TX, November 15-19, 1992, Pharm. Res. 9(10):S-309, 1992.
40. Bergstrom, R.F., Callaghan, J.T., Levine L.R., and Cerimele, B.J. The Interaction of
Ethanol and the H2-Receptor Antagonist Nizatidine in Normal Male Volunteers. Am. Assn. Pharm. Sci. 8th Annual Meeting, Orlando, FL, November 14-18, 1993, Pharm. Res. 10(10):S-301, 1993.
41. Kurtz, D.L., Bergstrom, R.F., Goldberg, M.J., and Cerimele, B. J. Drug Interaction
Between Sertraline and Desipramine or Imipramine. Am. Col. Clin. Pharmacol. 25th Annual Meeting, Orlando, FL, October 8, 1994, J. Clin. Pharmacol. 34:1030, 1994.
42. Nyhart, Jr., E.H., Cerimele, B.J., Kassahun, K., Callaghan, J.T., Bergstrom, R.F., and
Radtke, D.B. Olanzapine: An Initial Assessment of the Bioequivalence of Capsule and Tablet Formulations. Am. Assn. Pharm. Sci. 10th Annual Meeting, Miami, FL, November 6-9, 1995, Pharm. Res. 12(9):S-415, 1995.
43. Patel, B.R., Nyhart, Jr., E.H., Callaghan, J.T., Kassahun, K., Hunt, T.L., and Bergstrom,
R.F. Combined population Pharmacokinetic Analysis of Olanzapine in Healthy Volunteers. Am. Assn. Pharm. Sci. 10th Annual Meeting, Miami, FL, November 6-9, 1995, Pharm. Res. 12(9):S-360, 1995.
44. Bergstrom, R.F., Callaghan, J.T., Cerimele, B.J., Nyhart, Jr. E.H., Kassahun, K., and
Hunt T.L. Pharmacokinetics of Olanzapine in Elderly and Young. Am. Assn. Pharm. Sci. 10th Annual Meeting, Miami, FL, November 6-9, 1995, Pharm. Res. 12(9):S-358, 1995.
45. Patel, B.R., Kurtz, D.L., Callaghan, J.T., Beasley, C.M., and Bergstrom, R.F. Effect of
Smoking and Gender on Population Pharmacokinetics of Olanzapine. Am. Psych. Assn. Meeting, New York, NY, May 4-9, 1996.
46. Levy, N.B., Blumenfield, M., Beasley, C.M., Dubey, A.K., Solomon, R.J., Todd, R.,
Goodman, A. and Bergstrom R.F. Fluoxetine is Safe and Efficacious in Depressed Hemodialysis-Patients. Psychosomatics 37(2):211-211, 1996.
47. Bergstrom, R.F., Callaghan, J.T., Cerimele, B.J., Radtke, D.B., Tatum, D.E., Nyhart, Jr.
E.H., and Potkin SG. Pharmacokinetics of Olanzapine in Caucasian, Chinese, and Japanese Subjects. Am. Assn. Pharm. Sci. Annual Meeting, Seattle, WA, October 27-31, 1996, Pharm. Res. 13(9):S-424, 1996.
48. Bergstrom, R.F., Goldberg, M.J., Cerimele, B.J., Hatcher, B.L., and Simcox, E.A. Lack
of a Pharmacokinetic Drug Interaction Between Fluoxetine and Terfenadine. Am. Assn. Pharm. Sci. Annual Meeting, Seattle, WA, October 27-31, 1996, Pharm. Res. 13(9):S-433, 1996.
49. Patel, B.R., Kurtz, D. L., Callaghan, J.T., Beasley Jr., C.M., Bergstrom, R.F. Effects of
Smoking and Gender on Population Pharmacokinetics of Olanzapine in a Phase III Clinical Trial. PPDM-8064 Am. Assn. Pharm. Sci. Annual Meeting, Seattle, WA, October 27-31, 1996, Pharm. Res. 13(9):S-408, 1996.
50. Goldberg, M.J. Bergstrom, R.F., Cerimele, B.J., Thomasson, H.R., Hatcher, B.L., and
Simcox, E.A. Fluoxetine Effects on Pindolol Pharmacokinetics. Am. Soc. Clin. Pharmacol and Ther. Annual Meeting, San Diego, CA, March 1997, Clin. Pharmacol Ther. 61(2):178, 1997.
51. Mäenpää, J., Wrighton, S., Bergstrom, R., Cerimele, B., Tatum, D., Hatcher, B., and
Callaghan, J.T. Pharmacokinetic and Pharmacodynamic Interactions Between Fluvoxamine and Olanzapine. Am. Soc. Clin. Pharmacol and Ther. Annual Meeting, San Diego, CA, March, 1997, Clin. Pharmacol Ther. 61(2):225, 1997.
52. Maya J.F., Callaghan, J.T., Bergstrom, R.F., Cerimele, B.J., Kassahun, K., Nyhart Jr,
E.H., and Brater, D.C. Olanzapine and Warfarin Drug Interaction. Am. Soc. Clin. Pharmacol, Ther. Annual Meeting, San Diego, CA, March, 1997, Clin. Pharmacol Ther. 61(2):182, 1997.
53. Goldberg, M.J. Bergstrom, R.F., Smith, B.P., Simcox, E.A., Thomasson, H.R., and
Shipley, L.A. Melatonin: Pharmacokinetics and Effect on Body Temperature in Men, Am. Sleep Disorders Association, Sleep Res. Soc. 11th Annual Meeting, San Francisco, CA, June 10-15, 1997.
54. Bergstrom, R.F., Macias, W.L., Cerimele, B.J., Kassahun K., Hatcher, B.L., Radtke D.B.,
Tatum, D.E., and Callaghan J.T. Steady State Olanzapine Concentrations Do Not Affect Theophylline Pharmacokinetics. Am. Assn. Pharm. Sci. Annual Meeting, Boston, MA, November 2-6, 1997, (Abstract 3427) Pharm. Res. 14(11):S-605, 1997.
55. Bergstrom R., Mitchell M., Hatcher B., Witcher J., Jewell H., Richards J., and McEwen
J. Pharmacokinetics of Olanzapine in Healthy Male Subjects Following Intramuscular Administration of Single Doses. Am. Assn. Pharm. Sci. Annual Meeting, San Francisco, CA November 15-19, 1998, (Abstract 2052) PharmSci Supplement 1(1):S-152, 1998. http://www.aapsj.org/abstracts/AM_1998/2052.html
56. Cerimele B., Bergstrom R., Macias W., Callahgan J., and Miller J. Misapplication of
Bioequivalence Paradigm to Drug-Interaction Studies. Am. Assn. Pharm. Sci. Annual Meeting, San Francisco, CA November 15-19, 1998, (Abstract 3342) PharmSci Supplement 1(1):S-459, 1998. http://www.aapsj.org/abstracts/AM_1998/3797.html
57. Witcher J.W., Bergstrom R.F., Cerimele B.J., Hatcher B.L., Jewell H., Hemingway J.,
Ratnasingam L,. and Mitchell M. Pharmacokinetics and Bioequivalence of Olanzapine Rapidly-Disintegrating Tablets. Am. Assn. Pharm. Sci. Annual Meeting, San Francisco, CA November 15-19, 1998, (Abstract 3431) PharmSci Supplement 1(1):S-487, 1998. http://www.aapsj.org/abstracts/AM_1998/3431.html
58. Cerimele B., Bergstrom R., Callaghan J., and Clancy A. Statistical Methodology for
Assessing and Comparing Pharmacokinetic Dose-Response Relationships. Am. Assn. Pharm. Sci. Annual Meeting, San Francisco, CA November 15-19, 1998, (Abstract 3797) PharmSci Supplement 1(1):S-599, 1998. http://www.aapspharmsci.org/scientificjournals/pharmsci/am_abstracts/1998/abstracts/3797.html
59. Bergstrom R, Mitchell M, Jewell H, Richards J, McEwan J, Hatcher B. Examination of
the safety, tolerance, and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects. Schizophrenia Research 36(1-3):305-306, 1999
60. Wright P, Keisler G, Mitchell M, Jewell H, Hatcher B, Brook S, Bergstrom R. Safety and
efficacy of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis. Schizophrenia Research 36(1-3):318, 1999.
61. Wright P, Jewell H, Mitchell M, Hatcher B, Brook S, Kiesler G, Bergstrom R. A
preliminary study of the safety, efficacy, and pharmacokinetics of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis. Schizophrenia Research 36(1-3):318. 1999
61. Bergstrom R, Mitchell M, Cerimele B, Hatcher B, Jewell H, Satterwhite J, Harry J.
Direct Comparison of IM and Oral Olanzapine Pharmacokinetics in Healthy Male Subjects. AAPS Annual Meeting, New Orleans, LA November 1999, AAPS PharmSci 1(4):Abstract 3206, 1999. http://www.aapsj.org/abstracts/AM_1999/2363.htm
62. Satterwhite J, Cerimele B, Hatcher B, Tatum D, Thomasson H, Callaghan J, Bergstrom
R. Pharmacokinetic/Pharmacodynamic Drug Interation Evaluation of the Coadministration of Intramuscular Olanzapine with Intramuscular Lorazepam. AAPS Annual Meeting, New Orleans, LA November 1999, AAPS PharmSci 1(4):Abstract 2072, 1999. http://www.aapsj.org/abstracts/AM_1999/1172.htm
63. Sathirakul K, Teng L, Bergstrom RF, Wise SD. Olanzapine: Assessment of the
Pharmacokinetics in Chinese and Caucasian Subjects. AAPS Annual Meeting, Indianapolis, IN November 2000, AAPS PharmSci 2(4):Abstract 1861, 2000. http://www.aapsj.org/abstracts/AM_2000/3315.htm
64. Kuan HY, Reddy S, Zhang L, Knadler MP, Skinner M, Bergstrom RF. Duloxetine
Single- And Multiple-dose Pharmacokinetics In Healthy Subjects AAPS Annual Meeting, Toronto Ontario, Canada, November 2002, AAPS PharmSci 4(4):Abstract T3243, 2002. http://www.aapsj.org/abstracts/AM_2002/AAPS2002-001600.pdf
65. Kothare PA, Bergstrom RF, Lee KB, Sinha V. Pharmacokinetic Analysis Of Fluoxetine
Using Population Analyses In Caucasian Subjects With Major Depressive Disorder. AAPS Annual Meeting, Salt Lake City, Utah, November 2003, AAPS PharmSci 5(S1):Abstract T2347, 2003. http://www.aapsj.org/abstracts/Am_2003/AAPS2003-002163.PDF
66. Small D, Loghin C, Lucas R, Knadler MP, Zhang L, Chappell J, Bergstrom R, Callaghan
JT. Pharmacokinetic Evaluation of Combined Duloxetine and Fluvoxamine Dosing in CYP2D6 Poor Metabolizers. ASCPT Annual Meeting, Orlando, Florida, March 2-6, 2005. Clin Pharmacol Ther 77: P37-P37; doi:10.1016/j.clpt.2004.12.036 http://www.nature.com/clpt/journal/v77/n2/pdf/clpt2005150a.pdf
67. Sinha VP, Dai Y, Kothare P, Lee KB, Kurtz DL, Bergstrom RF. Population
Pharmacokinetic Analyses of Fluoxetine and Norfluoxetine in Patients. ASCPT Annual Meeting, Baltimore, Maryland, March 8-11, 2006. Clin Pharmacol Ther 79: P27-P27; doi:10.1016/j.clpt.2005.12.100 http://www.nature.com/clpt/journal/v79/n2/pdf/clpt2006114a.pdf
68. Bergstrom RF; Kryzhanovskaya L; Martenyi F; Osuntokun OO; Quinlan T; Tohen M;
Wang WV; Bowden CL; Smulevich AB. Olanzapine Plus Carbamazepine Versus Carbamazepine Plus Placebo in the Treatment of Mania: A 6-week, Double-blind, Randomized Trial Fifth European Stanley Conference on Bipolar Disorder (ESCBD/Stanley); 5-7 October 2006; Barcelona, Spain
69. Bergstrom RF; Kryzhanovskaya L; Osuntokun OO; Tohen M; Wang WV; Bowden CL;
Smulevich AB; Quinlan T; Martenyi F. Olanzapine Plus Carbamazepine Versus Carbamazepine in the Treatment of Mania: A 6-week, Double-blind, Randomized Trial. 45th American College of Neuropsychopharmacology; December 3-7, 2006; Hollywood, FL
70. Kurtz D, Bergstrom R, McDonnell DP, Mitchell M. Pharmacokinetics (PK) of Multiple
Doses of Olanzapine Long Acting Injection (OLAI), an Intramuscular (IM) Depot Formulation of Olanzapine (OLZ), in Stabilized Patients with Schizophrenia. Society of Biological Psychiatry 63rd Annual Convention, Washington, DC Biological Psychiatry 63(7):S1:288S May 3, 2008.
71. Garhyan P., Kurtz D. L., McDonnell D. P., Bergstrom R. F. Population Pharmacokinetic
Modeling of Long Acting Intramuscular Injection of Olanzapine Pamaote Depot. American Association of Pharmaceutical Scientists, Annual Meeting 2008. http://www.aapsj.org/abstracts/AM_2008/AAPS2008-001838.PDF
BIBLIOGRAPHY - JOURNAL PUBLICATIONS
Bergstrom, R.F., Fites, A.L., and Lamb, J.W. Stability of Parenteral Solutions of Tobramycin Sulfate. Am. J. Hosp. Pharm. 32:887-888, 1975.
Bergstrom, R.F., and Fites, A.L. Stability of Erythromycin Gluceptate in Sodium Chloride Injection and Dextrose Injection. Am. J. Hosp. Pharm. 32:241, 1975.
Agabeyoglu, I.T., Bergstrom, R.F., Gillespie, W.R., Wagner, J.G., and Kay, D.R. Plasma Protein Binding of Prednisolone in Normal Volunteers and Arthritic Patients. Europ. J. Clin. Pharmacol. 16:339-404, 1979.
Bergstrom, R.F., Kay, D.R., and Wagner, J.G. High-Performance Liquid Chromatographic Determination of Penicillamine in Whole Blood, Plasma, and Urine. J. Chromatogr. Biomed. Appl. 222:445-452, 1981.
Bergstrom, R.F., Kay, D.R., and Wagner, J.G. The In-Vitro Loss of Penicillamine in Plasma, Albumin Solution, and Whole Blood: Implications for Pharmacokinetic Studies of Penicillamine. Life Sciences 27:189-198, 1981.
Wagner, J.G., Wexler, D., Agabeyoglu, I.T., Bergstrom, R.F., Sakmar, E., and Kay, D.R. Plasma Protein-Binding Parameters of Prednisolone in Immune Disease. J. Lab. Clin. Med. 97:487-501, 1981.
Bergstrom, R.F., Kay, D.R., and Wagner, J.G. The Pharmacokinetics of Penicillamine in a Female Mongrel Dog. J. Pharmacokin. Biopharm. 9:603-621, 1981.
Bergstrom, R.F., Kay, D.R., and Wagner, J.G. Penicillamine Kinetics in Normal Subjects. Clin. Pharmacol. Ther. 30:404-413, 1981.
Ridolfo, A.S., Carmichael, R.H., DeSante, K.A., Bergstrom, R.F., Rockhold, F.W., Nash, J.F., and Fineberg, S.E. Clinical Pharmacology of Benoxaprofen. Europ. J. Rheum. Inflam. 5:(2):98-112, 1982.
10. Lemberger, L., Bergstrom, R., Aronoff, G., Farid, N. and Wolen, R. Specific Serotonin
Uptake Blockers: Clinical Pharmacology and Antidepressant Action. Clin. Neuropharmacol. 7(S1):324-325, 1984.
11. Aronoff, G.R., Bergstrom, R.F., Prottratz, S.T., Sloan, R.S., Wolen, R.L., and Lemberger,
L. Fluoxetine Kinetics and Protein Binding in Normal and Impaired Renal Function. Clin. Pharmacol. Ther., 36:138-144, 1984.
12. Callaghan, J.T., Bergstrom, R.F., Obermeyer, B.D., King, E.P. and Offen, W.W.
Intravenous Nizatidine Kinetics and Acid Suppression. Clin. Pharmacol. Ther. 37(2):162-165, 1985.
13. Lemberger, L., Rowe, H., Bergstrom, R.F., Farid, K.Z., Enas, G.G. The Effect of
Fluoxetine on the Psychomotor Performance, Physiologic Response, and Pharmacokinetic Disposition of Ethanol. Clin. Pharmacol. Ther. 37:658-664, 1985.
14. Farid, N.A., Bergstrom, R.F., Ziege, E.A., Parli, C.J., and Lemberger, L. Single-Dose
and Steady-State Pharmacokinetics of Tomoxetine in Normal Subjects. J. Clin. Pharmacol. 25:296-301, 1985.
15. Lemberger, L., Bergstrom, R.F., Wolen, R.L., Farid, N.A., Enas, G.G., and Aronoff, G.R.
Fluoxetine: Clinical Pharmacology and Physiologic Disposition. J. Clin. Psych. 46(3):14-19, 1985.
16. Knadler, M.P., Bergstrom, R.F., Callaghan, J.T., and Rubin, A. Nizatidine, An H2-
Blocker: Its Metabolism and Disposition in Man. Drug Metab. Dispos. 14(2):175-182, 1986.
17. Galloway, J.A., Root, M.A., Bergstrom, R., Spradlin, C.T., Howey, D.C., Fineberg, S.E.,
and Jackson, R.L. Clinical Pharmacologic Studies with Human Insulin (recombinant DNA). Diabetes Care 2(S5):13-22, 1982.
18. Callaghan, J.T., Bergstrom, R.F., Rubin, A., Chernish, S., Crabtree, R., Knadler, M.P.,
Obermeyer, B., Offen, W.W., Schneck, D.W., Aronoff, G., Lasseter, K.C. A Pharmacokinetic Profile of Nizatidine in Man. Scan. J. Gastero. 22(S136):9-17, 1987.
19. Callaghan, J.T., Rubin, A., Knadler, M.P., and Bergstrom, R.F. Nizatidine, an H2-
Receptor Antagonist: Disposition and Safety in the Elderly. J. Clin. Pharmacol. 27:618-624, 1987.
20. Knadler, M.P., Bergstrom, R.F., Callaghan, J.T., Obermeyer, B.D., and Rubin, A.
Absorption Studies of the H2-Blocker Nizatidine. Clin. Pharmacol. Ther. 42(5):514-520, 1987.
21. Lemberger, L., Rowe, H., Bergstrom, R., Bosomworth, J., and Tenbarge, J. The Effect of
Fluoxetine on the Pharmacokinetics and Psychomotor Responses of Diazepam. Clin. Pharmacol. Ther. 43(4):412-419, 1988.
22. Lemberger, L., Farid, N.A., Bergstrom, R.F. and Wolen, R.L. Fluoxetine, Pharmacology
and Physiologic Disposition. Int. J. Obesity 11(S3):157-161, 1987.
23. Aronoff, G.R., Bergstrom, R.F., Bopp, R.J., Sloan, R.S., and Callaghan, J.T. Nizatidine
Disposition in Subjects with Normal and Impaired Renal Function. Clin. Pharmacol. Ther. 43(6):688-695, 1988.
24. Bergstrom, R.F., Lemberger, L., Farid, N.A., and Wolen, R.L. Clinical Pharmacology
and Pharmacokinetics of Fluoxetine: A Review. Br. J. Psych. 153(S3):47-50, 1988.
25. Schenker, S., Bergstrom, R.F., Wolen, R.L., and Lemberger, L. Fluoxetine Disposition
and Elimination in Cirrhosis. Clin. Pharmacol. Ther. 44(3):353-359, 1988.
26. Lalka, S.G., Malone, J.M., Fischer, D.F., Jr., Bernhard, V.M., Sullivan, D.,
Stoeckelmann, D., and Bergstrom, R.F. Efficacy of Prophylactic Antibiotics in Vascular Surgery: An Atrerial Wall Microbioloogic and Pharmacokinetic Perspective. J. Vas. Surg. 10(5):501-510, 1989.
27. Bergstrom, R.F., and Lemberger L. First Time Studies in Man: An Industrial
Perspective. in Controversy V: Phase I, First Time in Man Studies. Ed. Colburn, W.A. J. Clin. Pharmacol. 30(3):210-222, 1990.
28. Schneck, D.W., Callaghan, J.T., Bergstrom, R.F., Obermeyer, B.D., and Offen, W.W.
Relationship Between Steady-State Plasma Nizatidine Concentrations and Inhibition of Basel and Stimulated Gastric Acid Secretion. Clin. Pharmacol. Ther. 47(4):499-503, 1990.
29. Obermeyer, B.D., Bergstrom, R.F., Callaghan J.T., Knadler M.P., Golichowski A., and
Rubin A. Secretion of Nizatidine into Human Breast Milk after Single and Multiple Doses. Clin. Pharmacol. Ther. 47(6):724-730, 1990.
30. Kreis, W., Budman, D.R., Freeman, J., Bergstrom, R.F., and Nelson, R.L. Clinical
Pharmacokinetics of Intravenously Injected Tritiated Vinzolidine. Cancer Chemother. Pharmacol. 26:419-422, 1990.
31. Bergstrom, R.F., Peyton, A.L., and Lemberger, L. Quantification and Mechanism of the
Fluoxetine and Tricyclic Antidepressant Interaction. Clin. Pharmacol. Ther. 51(3):239-248, 1992.
32. Bergstrom, R.F., Beasley, C.M., Levy, N.B., Blumenfield M., and Lemberger, L. The
Effect of Renal and Hepatic Disease on the pharmacokinetics, Renal Tolerance, and Risk-Benefit Profile of Fluoxetine. Internat. Clin. Psychopharmacol. 8(4):261-266, 1993.
33. Levy, N.B., Blumenfield, M., Beasley, C.M., Dubey, A.K., Solomon, R.J., Todd, R.,
Goodman, A. and Bergstrom R.F. Fluoxetine in Depressed-Patients with Renal-Failure and in Depressed-Patients with Normal Kidney-Function. Gen. Hosp. Psy. 18(1):8-13, 1996.
34. Kurtz, D.L., Bergstrom, R.F., Goldberg, M.J. and Cerimele, B.J. The Effect of Sertraline
on the Pharmacokinetics of Desipramine and Imipramine. Clin. Pharmacol. Ther. 62(2):145-56, 1997.
35. Bergstrom, R.F., Goldberg, M.J., Cerimele, B.J., and Hatcher, B.L. Assessment of the
Potential for a Pharmacokinetic Interaction Between Fluoxetine and Terfenadine. Clin. Pharmacol. Ther. 62:643-51 1997.
36. Blumenfield M., Levy N.B., Spinowitz B, Charytan C., Beasley C.M. Jr., Dubey A.K.
Solomon R.J., Todd R., Goodman A., Bergstrom R.F. Fluoxetine in Depressed Patients on Dialysis. Internat. J. Psyc. in Med. 27(1):71-80 1997.
37. Lucas R.A., Gilfillan D.J., and Bergstrom R.F. A Pharmacokinetic Interaction Between
Carbamazepine and Olanzapine: Observations on Possible Mechanism. European J Clin Pharmacol. 54:639-43 1998.
38. Macias, W.L., Bergstrom, R.F., Cerimele, B.J., Kassahun K., Tatum, D.E., and
Callaghan J.T. Lack of a Pharmacokinetic Interaction Between Olanzapine and Theophylline. Pharmacotherapy 18(6):1237-1248 1998.
39. Callaghan J.T., Bergstrom R.F., Ptak L.R., and Beasley C.M. Jr. Olanzapine:
Pharmacokinetics, Pharmacodynamics, and Clinical Trial Profile. Clinical Pharmacokinetics 37(3):177-193 1999.
40. Grothe D.R., Calis K.A., Jacobsen L., Kumra S., DeVane C.L., Rapoport J.L., Bergstrom
R.F., and Kurtz D.L. Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients with Childhood Onset Schizophrenia. J Clin Psychopharmacol. 20(2):220-5, 2000.
41. Sathirakul K., Chan C., Teng L., Bergstrom R.F., Yeo K.P., Wise S.D. Olanzapine
Pharmacokinetics Are Similar in Chinese and Caucasian Subjects. Br. J. Clin. Phamacol. 56:184-187, 2003.
42. Lobo ED. Loghin C. Knadler MP. Quinlan T. Zhang L. Chappell J. Lucas R. Bergstrom
RF. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clinical Pharmacokinetics. 47(2):103-9, 2008.
43. Lobo ED. Bergstrom RF. Reddy S. Quinlan T. Chappell J. Hong Q. Ring B. Knadler MP.
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clinical Pharmacokinetics. 47(3):191-202, 2008.
44. Tohen M. Bowden CL. Smulevich AB. Bergstrom R. Quinlan T. Osuntokun O. Wang
WV. Oliff HS. Martenyi F. Kryzhanovskaya LA. Greil W. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. British Journal of Psychiatry. 192(2):135-43, 2008 Feb.
45. Citrome L. Stauffer VL. Chen L. Kinon BJ. Kurtz DL. Jacobson JG. Bergstrom RF.
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. Journal of Clinical Psychopharmacology. 29(3):278-83, Jun 2009.
46. Kane J.M., Detke H.C., Naber D., Sethuraman G., Lin D.Y., Bergstrom R.F., and
McDonnellD. Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. Am J Psychiatry 167: 181 - 189 Feb 2010.
47. Lobo E.D., Robertson-Plouch C., Quinlan T., Hong Q., Bergstrom R.F. Oral Olanzapine
Disposition in Adolescents with Schizophrenia or Bipolar I Disorder: A Population Pharmacokinetic Model. Paediatr Drugs 2010 Jun;12(3):201-11.
48. McDonnell D.P., Detke H.C., Bergstrom R.F., Kothare P., Johnson J., Stickelmeyer M.,
Sanchez-Felix M.V., Sorsaburu S., and Mitchell M.I. Post-injection Delirium/Sedation Syndrome in Patients with Schizophrenia Treated with Olanzapine Long-Acting Injection: II. Investigations of Mechanism. BMC Psychiatry 2010 Jun 10;10:45.
49. Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics
and drug interactions. Clin Pharmacokinet. 2011 May 1;50(5):281-94.
50. Mitchell M, Kothare P, Bergstrom R, Zhao F, Jen KY, Walker D, Johnson J, McDonnell
D. Single and Multiple-Dose Pharmacokinetics, Safety and Tolerability Profiles of Olanzapine Long-Acting Injection (LAI) in Patients with Schizophrenia. Clin Ther. (in press) 2011.
BIBLIOGRAPHY- BOOKS AND CHAPTERS
Quay, J.F., and Bergstrom, R.F. Pharmacology and Pharmacokinetics of Penicillins. In Beta-Lactam Antibiotics For Clinical Use. Ed. Queener, S.F., Webber, A.J., and Queener, S.W. Marcel Dekker Inc., New York, pp 163-224, 1986.
Kroboth, P.D., Schwinghammer, T.L., and Bergstrom, R.F. H Antagonists: Choosing a
Model. In Pharmacokinetics and Pharmacodynamics: Current Problems, Potential Solutions. Ed. Kroboth, P.D., Smith, R.B., and Juhl, R.P. Harvey Whitney Books Company, Cincinnati, Ohio, pp 10-28, 1988. Library of Congress: 88-050443
Bergstrom RF, Callaghan JT, Cerimele BJ, Kurtz, DL, and Hatcher BL. Population Pharmacokinetics and Plasma Concentrations of Olanzapine. In Olanzapine (Zyprexa®): A Novel Antipsychotic edited by Tran PV, Bymaster FP, Tye N, Herrera JM, Brier A, and Tollefson, GD. Lippincott, Williams and Wilkins, Philladelphia 2000, pp 232-252.
Callaghan JT, and Bergstrom RF. Olanzapine: Drug Interactions. In Olanzapine (Zyprexa®): A Novel Antipsychotic edited by Tran PV, Bymaster FP, Tye N, Herrera JM, Brier A, and Tollefson, GD. Lippincott, Williams and Wilkins, Philladelphia 2000, pp 253-264.
REFERENCES
Dr. Ho-Leung Fung, University at Buffalo, State University of New York, Buffalo, NY 14260
Professor of Pharmaceutical Sciences email: hlfung@acsu.buffalo.edu Phone: 716-645-4843
Dr. David Smith, University of Michigan, Ann Arbor, MI 48109
Professor and Chair of Pharmaceutical Sciences email: smithb@umich.edu Phone: 734-647-1431
Dr. Lisa Shipley, Merck and Co., Inc., West Point, PA 19486
Vice President & Global Head Drug Metabolism and Pharmacokinetics email: lisa_shipley2@merck.com Phone: 215-652-6128
Dr. Sandra R. B. Allerheiligen, Merck and Co., Inc. West Point, PA 19486
Vice President of Modeling and Clinical Trial Simulation email: sandra.allerheiligen@merck.com Phone: 267-305-3086
Dr. Gregg Lundeen, Eli Lilly and Co., Indianapolis, IN 46285
Vice President Toxicology, Drug Disposition, and PK/PD email: grl@lilly.com Phone: 317-277-1608
REVISED: OCTOBER, 2011
Original Research Received: August 11, 2005 Accepted after revision: March 15, 2006 Enhanced External Counterpulsation Reduces Lung/Heart Ratio at Stress in Patients with Coronary Artery Disease Chii-Ming Lee a Yen-Wen Wu a Hsiang-Yiang Jui a Ming-Fong Chen a a National Taiwan University Hospital, Taipei , Taiwan; b University of Pittsburgh, Pittsburgh, Pa. , USA Key Words
Undergraduate awards ceremony, Nov. 2, 2009 SCOTIA-GLENVILLE HIGH SCHOOL UNDERGRADUATE AWARDS ASSEMBLY Pledge of Allegiance and Musical Arrangement THE SCOTIA-GLENVILLE HIGH SCHOOL FRESHMAN YEAR ACHIEVEMENT AWARD Medal – to members of the Class of 2012 with the highest achievement during the first year in high school: Matthew Ashcroft, Kul en Bailey, Nicholas Conlon, Sarah Dean, Nicole H